師資
個人簡介
方沈應，南方科技大學公共衛(wèi)生及應急管理學院教授、研究員、博士生導師。獲美國德克薩斯大學生物統(tǒng)計學博士，曾任德克薩斯大學MD安德森癌癥研究中心腫瘤外科系助理教授、副教授，武漢科技大學特聘教授，廣州醫(yī)科大學“南山學者”特聘教授。任PLOS ONE、Advances in Public Health 及 Frontiers in Oncology雜志編輯，擔任American Journal of Human Genetics、Journal of National Cancer Institute、PLOS Genetics、International Journal of Cancer、Carcinogenesis以及Scientific Reports等13本英文雜志評委，并參與National Science Center (NCN panel NZ7， Poland)和中國國家自然基金委基金評審；為美國癌癥協(xié)會、遺傳學會和統(tǒng)計學會會員。主要運用流行病學與生物統(tǒng)計學方法研究環(huán)境因素、遺傳因素與惡性腫瘤或慢性病的發(fā)生、發(fā)展及預后的關系。參與收集了北美最大的黑色素瘤病例對照研究人群并創(chuàng)建了北美黑色素瘤風險預測模型。目前主要運用遺傳學、生物信息學及機器學習法，深度挖掘研究病人個體基因組學特征、疾病臨床表現(xiàn)信息，包括影像學資料和病理組織學染色圖片等醫(yī)療大數據，為腫瘤的早期診斷、個體化治療、疾病復發(fā)及生存預后提供相應依據。研究成果發(fā)表于J Clin Oncol.（第一作者3篇， 共同作者5篇）, J Invest Dermatol.（通訊作者4篇）, Nature Genetics（4篇），Int J Cancer（第一作者3篇， 共同作者6篇），The Lancet Oncology（1篇），Cancer（6篇）等國際著名刊物。近期的研究成果被Cancer network、NEJM等專業(yè)媒體報道, 于2011美國遺傳學年會及2020年全球華人統(tǒng)計學年會獲大會報告, 在SCI等刊物發(fā)表英文論文70余篇。
研究方向
1. 人群流行病學研究：依據大灣區(qū)人群樣本，開展人群流行病學觀察研究，調查研究環(huán)境因素與遺傳因素在慢性病、腫瘤或新發(fā)傳染病發(fā)生、發(fā)展中的作用，為采取干預措施以降低疾病的發(fā)病風險提供依據。
2. 健康醫(yī)療大數據應用：（1）依托附屬醫(yī)院及合作醫(yī)療單位，收集腫瘤病人的血液及組織樣本，建立患者醫(yī)療數據庫；（2）結合TCGA腫瘤數據庫及本地醫(yī)院人群標本庫，同MD安德森研究中心、Baylor醫(yī)學院以及St Jude兒童醫(yī)院等開展多中心合作，整合分析多組學—基因組、轉錄組、表觀基因組、蛋白組及代謝組學等多層組學數據，同時納入人口統(tǒng)計學或臨床表型變量，應用統(tǒng)計學與人工智能新理論—神經網絡模型（CNN）、變分自編碼器模型(VAE)以及條件生成對抗網絡模型（CGAN），對高維數據降維并壓縮提取特征變量，以預測疾病的發(fā)生、發(fā)展及預后，并為精準治療提供依據；（3）機器學習及數據科學在醫(yī)療影像資料—數字化組織病理學圖像、CT、MRI等中的應用，包括質量控制、聚類分割、標識、特征提取及結果預測，為提高疾病的診斷、危險度分層及指導精準治療和預后評估提供依據，并且可藉此發(fā)展出新的治療手段與科技轉化平臺；發(fā)展機器學習新模型-Transformer，并應用于圖像處理分析以及識別腫瘤驅動基因；（4）協(xié)同附屬醫(yī)院，開展臨床流行病學研究，科學實施臨床實驗設計與診斷性試驗評價,以及針對治療方案開展衛(wèi)生經濟學評估與決策分析，為政策制訂者提供依據。
3. 生物信息學研究：評估腫瘤微環(huán)境中的免疫細胞、腫瘤細胞及間質細胞的構成演變在腫瘤轉移、預后與治療中的作用。
4. 疾病病因學推論：孟德爾隨機化研究設計及病因推論；運用加性噪聲模型進行因果關聯(lián)分析。
5. 統(tǒng)計學模型在遺傳流行病學中的應用：多因子風險評估、基因-基因，基因-環(huán)境交互作用。
教育經歷
2004/08-2008/12，美國德克薩斯大學生物統(tǒng)計學，博士
2003/01-2004/07，美國德克薩斯大學生物統(tǒng)計學，碩士
1996/08-1999/07，第四軍醫(yī)大學流行病學，碩士
1989/09-1994/07，同濟醫(yī)科大學預防醫(yī)學，學士
工作經歷
2022/05–至今， 南方科技大學公共衛(wèi)生及應急管理學院，教授、研究員、博士生導師
2019/09-2022/04，美國德克薩斯大學MD安德森腫瘤研究中心腫瘤外科系，副教授
2012/10-2019/08，美國德克薩斯大學MD安德森腫瘤研究中心腫瘤外科系，助理教授
2011/09-2012/09，美國德克薩斯大學MD安德森腫瘤研究中心遺傳學系，講師
2009/01-2011/08, 美國德克薩斯大學MD安德森腫瘤研究中心，博士后
1999/08-2002/12，軍事醫(yī)學科學院微生物流行病研究所，助理研究員
1994/08-1996/07，中國學校衛(wèi)生雜志社，編輯
科研項目
1. 美國國立衛(wèi)生研究院，“Integration of Clinical and Molecular Biomarkers for Melanoma Survival”。
2. 安德森研究中心研究項目，“The skin microbiome and cutaneous melanoma”。
3. 國家自然科學基金面上項目，“結直腸癌腫瘤微環(huán)境免疫細胞浸潤標志物及其對患者預后生存的影響”。
4. 國家自然科學基金面上項目，“應用第二代測序和生物信息學技術研究腸道微生物群系與大腸癌發(fā)病之間的關系”。
5. 美國國立衛(wèi)生研究院，“Genetic polymorphisms of IL‐12p35 and IL‐23p19 in melanoma progression”。
6. 美國國立衛(wèi)生研究院職業(yè)發(fā)展項目，“C-reactive protein and melanoma outcomes”。
7. 美國國立衛(wèi)生研究院，“Genetic determinants of Breslow tumor thickness and their impact on melanoma progression”。
8. 美國國立衛(wèi)生研究院，“Cancer Center Support Grant – Melanoma Program”。
9. 美國國立衛(wèi)生研究院, “UT M. D. Anderson Cancer Center SPORE in Melanoma-CoreA”。
代表性論文（#共同一作，*通訊作者）
1. Wang Y#, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE*. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2021 Dec 21:S0022-202X(21)02627-0. doi: 10.1016/j.jid.2021.12.012. (SCI IF = 7.14)
2. Liu W#, Zhang R, Shu R, Yu J, Li H, Long H, Jin S, Li S, Hu Q, Yao F, Zhou C, Huang Q, Hu X, Chen M, Hu W, Wang Q*, Fang S*, Wu Q*. Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing. BioMed Research International 2020:7828392,2020(SCI IF = 2.276)
3. Fang S#, Hu Z, Xu T, Zhang K, Li S, Xiong M*. Mass testing and containment of Covid-19. J Emerg Med Truma Surg Care. S1:001. 6/2020. (SCI IF = 0.76)
4. Ge Q#, Huang X, Fang S, Guo S, Liu Y, Lin W, Xiong M*. (2020). Conditional Generative Adversarial Networks for Individualized Treatment Effect Estimation and Treatment Selection. Frontiers in genetics, (2020): 585804. (SCI IF = 4.15)
5. Feng R#, Wang Y#, Ramachandran V, Ma Q, May M, Li M, Zhou J, Xu X, Xu K, Fang S, Xia W, Sui D, Liu H, Gao X, Prieto V, Blacklow S, Lu M*, Lee J*. (2020). Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. Journal of experimental & clinical cancer research : CR, no. 1 (2020): 273. (SCI IF = 7.038)
6. Fang S*#, Lu J, Zhou X, Wang Y, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Sui D, Amos CI, Lee JE*. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 Jun 17;41(4):452-457. doi: 10.1093/carcin/bgz173. (SCI IF = 3.92)
7. Fang S#*, Xu T, Xiong M, Zhou X, Wang Y, Haydu LE, Ross MI, Gershenwald JE, Prieto VG, Cormier JN, Wargo J, Sui D, Wei Q, Amos CI, Lee JE*. Role of immune response, inflammation and tumor immune response–related cytokines/chemokines in melanoma progression. J Invest Dermatol. 2019 Jun 7. doi: 10.1016/j.jid.2019.03.1158. (SCI IF = 7.14)
8. Fang S #*, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL Reveille JD, Wei Q, Amos CI, Lee JE*. Association between body mass index, C-reactive protein levels and melanoma patient outcome. J Invest Dermatol. doi: 10.1016/j.jid.2017.04.007. (SCI IF = 7.14)
9. Fang S#, Sui D, Wang Y, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE*. Association of vitamin D levels with melanoma patient outcome after adjustment for C-reactive protein. Journal of Clinical Oncology. 2016 May 20:1741-1747. PMID: 27001565 (SCI IF = 32.96)
10. Fang S#, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JM, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett Jr. RL, Wang L, Wei Q, Amos CI, Lee JE*. C-reactive protein as a marker of melanoma progression. Journal of Clinical Oncology 2015 Apr 20;33(12):1389-96. Epub 2015 Mar 16. PMID: 25779565 (SCI IF = 32.96).
11. Fang S#, Wang Y, Amos CI, Lee JE*. Reply to Z. Li et al. Journal of Clinical Oncology e-Pub 8/2015. (SCI IF = 32.96)
12. Fang S #*, Vaysse A#, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE*. Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness. J Invest Dermatol. e-Pub 8/ 2016. PMID: 27506587. (SCI IF = 7.14)
13. Fang S*, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JM, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang L-E, Wei Q, Amos CI, Lee JE*. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep;135(9):2266-2272 (SCI IF = 7.14)
14. Fang S #*, Wang Y, Lu M, Dang Y, Li M,Koshkina N, Feng R, Liu H, Xu K, Sui D, Wei Q, Amos CI, Lee JE*. Association of Inflammation-related Genetic Variants with Melanoma Development. Journal of Experimental Dermatology and Research 1(3):012, 5/ 2015 (Invited article).
15. Fang S #, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Gardner JM, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett Jr. RL, Wang L, Wei Q, Amos CI, Lee JE*. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2014. doi: 10.1002/ijc.29182. (SCI IF = 5.14)
16. Fang S#, Krahe R, Bachinski LL, Zhang B, Amos CI*, Strong LC*. Sex-specific effect of TP53 PIN3 polymorphism on tumor risk in a cohort study of TP53 germline mutation carriers. Human Genetic. 2011 Dec;130(6):789-94. Epub 2011 Jun 19. (SCI IF = 3.54)
17. Fang S#, Fang X, Xiong M*. Psoriasis prediction from genome-wide SNP profiles. BMC dermatology. 2011 Jan 7; 11(1)1. (SCI IF = 1.70)
18. Fang S#, Pinney SM, Bailey-Wilson JE, de Andrade MA, Li Y, Kupert E, You M, Schwartz AG, Yang P, Anderson MW, Amos CI*. Ordered subset analysis identifies loci influencing lung cancer risk on chromosomes 6q and 12q. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3157-66. (SCI IF = 4.55)
19. Fang S#, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI*. Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations. PLoS One 2010 5(5): e10813. doi:10.1371/journal.pone.0010813. (SCI IF = 2.77)
20. Fang S#, Han J, Zhang M, Wang LE, Wei Q, Amos CI, Lee JE*. Joint effect of multiple common SNPs predicts melanoma susceptibility. PLoS One. 2013 Dec 31;8(12):e85642. doi: 10.1371/journal.pone.0085642. eCollection 2013. (SCI IF = 2.77)
21. Brossard M #, Fang S#, Vaysse A, Wei Q, Chen WV, Mohamdi H, Maubec E, Lavielle N, Galan P, Lathrop M, Avril MF, Lee JE, Amos CI#, Demenais F*. Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk. Int J Cancer. e-Pub 4/2015. (SCI IF = 5.14)
22. Vaysse A#, Fang S#, Brossard M#, Wei Q, Chen WV, Mohamdi H, Vincent-Fetita L, Margaritte-Jeannin P, Lavielle N, Maubec E, Lathrop M, Avril MF, Amos CI, Lee JE*, Demenais F*. A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants. Int J Cancer 139(9):2012-20, 11/2016. e-Pub 7/2016. PMID: 27347659. (SCI IF = 5.14)
23. Landi MT#*, Bishop DT, MacGregor S, Machiela MJ, Stratigos AJ, Ghiorzo P, Brossard M, Calista D, Choi J, Fargnoli MC, Zhang T, Rodolfo M, Trower AJ, Menin C, Martinez J, Hadjisavvas A, Song L, Stefanaki I, Scolyer R, Yang R, Goldstein AM, Potrony M, Kypreou KP, Pastorino L, Queirolo P, Pellegrini C, Cattaneo L, Zawistowski M, Gimenez-Xavier P, Rodriguez A, Elefanti L, Manoukian S, Rivoltini L, Smith BH, Loizidou MA, Del Regno L, Massi D, Mandala M, Khosrotehrani K, Akslen LA, Amos CI, Andresen PA, Avril MF, Azizi E, Soyer HP, Bataille V, Dalmasso B, Bowdler LM, Burdon KP, Chen WV, Codd V, Craig JE, Debniak T, Falchi M, Fang S, Friedman E, Simi S, Galan P, Garcia-Casado Z, Gillanders EM, Gordon S, Green A, Gruis NA, Hansson J, Harland M, Harris J, Helsing P, Henders A, Hocevar M, H?iom V, Hunter D, Ingvar C, Kumar R, Lang J, Lathrop GM, Lee JE, Li X, Lubinski J, Mackie RM, Malt M, Malvehy J, McAloney K, Mohamdi H, Molven A, Moses EK, Neale RE, Novakovic S, Nyholt DR, Olsson H, Orr N, Fritsche LG, Puig-Butille JA, Qureshi AA, Radford-Smith GL, Randerson-Moor J, Requena C, Rowe C, Samani NJ, Sanna M, Schadendorf D, Schulze HJ, Simms LA, Smithers M, Song F, Swerdlow AJ, van der Stoep N, Kukutsch NA, Visconti A, Wallace L, Ward SV, Wheeler L, Sturm RA, Hutchinson A, Jones K, Malasky M, Vogt A, Zhou W, Pooley KA, Elder DE, Han J, Hicks B, Hayward NK, Kanetsky PA, Brummett C, Montgomery GW, Olsen CM, Hayward C, Dunning AM, Martin NG, Evangelou E, Mann GJ, Long G, Pharoah PDP, Easton DF, Barrett JH, Cust AE, Abecasis G, Duffy DL, Whiteman DC, Gogas H, De Nicolo A, Tucker MA, Newton-Bishop JA, GenoMEL Consortium, Q-MEGA and QTWIN Investigators, ATHENS Melanoma Study Group, 23andMe, SDH Study Group, IBD Investigators, Essen-Heidelberg Investigators, AMFS Investigators, MelaNostrum Consortium, Peris K, Chanock SJ, Demenais F, Brown KM, Puig S, Nagore E, Shi J, Iles MM, Law MH*. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nat Genet 52(5):494-504, 5/2020. e-Pub 4/2020. PMCID: PMC7255059. (SCI IF = 21.11)
24. McQuade JL#*, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee D-Y, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob J-J, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA*: The association of BMI and outcomes in metastatic melanoma: A retrospective, multicohort analysis of patients treated with targeted therapy, immunotherapy, or chemotherapy. The Lancet Oncology.2018;19:310-322. (SCI IF = 33.80)
25. Liu S#, Wang Y, Wu W, Zhu D, Amos CI, Fang S, Lee JE, Han J, Wei Q*. Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival. Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30785.
26. Srokowski TP#, Fang S, Hortobagyi GN, Giordano SH*. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol. 2009 May 1;27(13):2170-6. Epub 2009 Mar 23. (SCI IF = 32.96)
27. Patt DA#, Duan Z, Fang S, Hortobagyi GN, Giordano SH*. Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk. J. Clin. Oncol., 2007; 25(25): 3871 – 3876. (SCI IF = 32.96)
28. Du XL#*, Lairson DR, Begley CE, Fang S . Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From Large Population-Based Cohort. J. Clin. Oncol., 2005, 23(34): 8620-8628. (SCI IF = 32.96)
29. Badgwell BD#, Giordano SH, Duan Z, Fang S , Bedrosian I, Kuerer HM, Singletary SE, Hunt KK, Hortobagyi GN, and Babiera G*. Mammography Before Diagnosis Among Women Age 80 Years and Older With Breast Cancer. J Clin Oncol;2008,26(15): 2482–2488. (SCI IF = 32.96)
30. Chavez- MacGregor M#, Zhao H, Kroll M, Fang S ,Zhang N, Hortobagyi GN, Buchholz TA, Shih T, Giordano SH*. Risk factors and incidence of TEE in older men and women with breast cancer. Annals of Oncology. 2011 Mar 10: mdq777v1-mdq777. (SCI IF = 18.27)
31. Telomeres Mendelian Randomization Collaboration#, Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, Wade KH, Timpson NJ, Evans DM, Willeit P, Aviv A, Gaunt TR, Hemani G, Mangino M, Ellis HP, Kurian KM, Pooley KA, Eeles RA, Lee JE, Fang S , Chen WV, Law MH, Bowdler LM, Iles MM, Yang Q, Worrall BB, Markus HS, Hung RJ, Amos CI, Spurdle AB, Thompson DJ, O'Mara TA, Wolpin B, Amundadottir L, Stolzenberg-Solomon R, Trichopoulou A, Onland-Moret NC, Lund E, Duell EJ, Canzian F, Severi G, Overvad K, Gunter MJ, Tumino R, Svenson U, van Rij A, Baas AF, Bown MJ, Samani NJ, van t'Hof FN, Tromp G, Jones GT, Kuivaniemi H, Elmore JR, Johansson M, Mckay J, Scelo G, Carreras-Torres R, Gaborieau V, Brennan P, Bracci PM, Neale RE, Olson SH, Gallinger S, Li D, Petersen GM, Risch HA, Klein AP, Han J, Abnet CC, Freedman ND, Taylor PR, Maris JM, Aben KK, Kiemeney LA, Vermeulen SH, Wiencke JK, Walsh KM, Wrensch M, Rice T, Turnbull C, Litchfield K, Paternoster L, Standl M, Abecasis GR, SanGiovanni JP, Li Y, Mijatovic V, Sapkota Y, Low SK, Zondervan KT, Montgomery GW, Nyholt DR, van Heel DA, Hunt K, Arking DE, Ashar FN, Sotoodehnia N, Woo D, Rosand J, Comeau ME, Brown WM, Silverman EK, Hokanson JE, Cho MH, Hui J, Ferreira MA, Thompson PJ, Morrison AC, Felix JF, Smith NL, Christiano AM, Petukhova L, Betz RC, Fan X, Zhang X, Zhu C, Langefeld CD, Thompson SD, Wang F, Lin X, Schwartz DA, Fingerlin T, Rotter JI, Cotch MF, Jensen RA, Munz M, Dommisch H, Schaefer AS, Han F, Ollila HM, Hillary RP, Albagha O, Ralston SH, Zeng C, Zheng W, Shu XO, Reis A, Uebe S, Hüffmeier U, Kawamura Y, Otowa T, Sasaki T, Hibberd ML, Davila S, Xie G, Siminovitch K, Bei JX, Zeng YX, F?rsti A, Chen B, Landi S, Franke A, Fischer A, Ellinghaus D, Flores C, Noth I, Ma SF, Foo JN, Liu J, Kim JW, Cox DG, Delattre O, Mirabeau O, Skibola CF, Tang CS, Garcia-Barcelo M, Chang KP, Su WH, Chang YS, Martin NG, Gordon S, Wade TD, Lee C, Kubo M, Cha PC, Nakamura Y, Levy D, Kimura M, Hwang SJ, Hunt S, Spector T, Soranzo N, Manichaikul AW, Barr RG, Kahali B, Speliotes E, Yerges-Armstrong LM, Cheng CY, Jonas JB, Wong TY, Fogh I, Lin K, Powell JF, Rice K, Relton CL, Martin RM, Davey Smith G. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017 May 1;3(5):636-651. doi: 10.1001/jamaoncol.2016.5945. (SCI IF = 24.80)
32. Law MH#*, Bishop DT, Lee JE, Brossard M, Martin NG, Moses EK, Song F, Barrett JH, Kumar R, Easton DF, Pharoah PD, Swerdlow AJ, Kypreou KP, Taylor JC, Harland M, Randerson-Moor J, Akslen LA, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, D?bniak T, Duffy DL, Elder DE, Fang S, Friedman E, Galan P, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Helsing P, Hocevar M, H?iom V, Ingvar C, Kanetsky PA, Chen WV, GenoMEL Consortium, Essen-Heidelberg Investigators, SDH Study Group, Q-MEGA and QTWIN Investigators, AMFS Investigators, ATHENS Melanoma Study Group, Landi MT, Lang J, Lathrop GM, Lubinski J, Mackie RM, Mann GJ, Molven A, Montgomery GW, Novakovic S, Olsson H, Puig S, Puig-Butille JA, Qureshi AA, Radford-Smith GL, van der Stoep N, van Doorn R, Whiteman DC, Craig JE, Schadendorf D, Simms LA, Burdon KP, Nyholt DR, Pooley KA, Orr N, Stratigos AJ, Cust AE, Ward SV, Hayward NK, Han J, Schulze HJ, Dunning AM, Bishop JA, Demenais F, Amos CI, MacGregor S, Iles MM*. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet. e-Pub 8/2015. (SCI IF = 21.11)
33. Iles MM#*, Law MH, Stacey SN, Han J, Fang S, Pfeiffer R, et al.. A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet. 2013 Apr;45(4):428-32, 432e1. doi: 10.1038/ng.2571. Epub 2013 Mar 3. (SCI IF = 21.11)
34. Amos CI#*, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S. et al 2011. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Human Molecular Genetics. 2011 Dec 15; 20(24):5012-23. Epub 2011 Sep 17. (SCI IF = 5.10)
35. Xiao F#, Ma J, Cai G, Fang S, Lee JE, Wei Q, Amos CI*. Natural and orthogonal model for estimating gene-gene interactions applied to cutaneous melanoma. Hum Genet. 2014 May;133(5):559-74. doi: 10.1007/s00439-013-1392-2. Epub 2013 Nov 17.
36. Giordano SH#, Fang S, Duan Z, Kuo Y, Hortobagyi GN, and Goodwin JS*. Use of Intravenous Bisphosphonates in Older Women with Breast Cancer. Oncologist. 2008; 13: 494 - 502.
37. Yang L#, Lu X, Deng J, Zhou Y, Huang D, Qiu F, Yang X, Yang R, Fang W, Ran P, Zhong N, Zhou Y, Fang S, Lu J*. Risk factors shared by COPD and lung cancer and mediation effect of COPD: two center case-control studies. Cancer Causes Control. 2015 Jan;26(1):11-24. doi: 10.1007/s10552-014-0475-2. Epub 2014 Dec 7.
38. Song F#, Amos CI, Lee JE, Lian CG, Fang S, Liu H, MacGregor S, Iles MM, Lindeman NI, Montgomery GW, Duffy DL, Cust AE, Jenkins MA, Whiteman DC, Kefford RF, Giles GG, Armstrong BK, Aitken JF, Hopper JL, Brown KM, Martin NG, Mann GJ, Bishop DT, Newton Bishop JA, the GenoMEL consortium, Kraft P, Qureshi AA, Kanetsky PA, Hayward NK, Hunter DJ, Wei Q, Han J*. Identification of a melanoma susceptibility locus and somatic mutation in TET2. Carcinogenesis. e-Pub 6/2014.
39. Park JY#, Amankwah EK, Anic GM, Lin HY, Walls B, Park H, Krebs K, Madden M, Maddox K, Marzban S, Fang S, Chen W, Lee JE, Wei Q, Amos CI, Messina JL, Sondak VK, Sellers TA, Egan KM*. Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):827-34. doi: 10.1158/1055-9965.EPI-12-1129. Epub 2013 Mar 5.
40. Zhang W#, Liu H, Liu Z, Zhu D, Amos CI, Fang S, Lee JE, Wei Q*. Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. e-Pub 5/2015.
41. Gorlov IP#*, Logothetis CJ, Fang S, Gorlova OY, Amos CI. Building a Statistical Model for Predicting Cancer Genes. PLOS One 7(11):e49175, doi:10.1371/journal.pone.0049175, 2012.
42. Du XL#*, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, Xing Y, Gor BJ, Chan W. Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma. Cancer 2006,106(6):1276-1285.
43. Srokowski TP#, Fang S, Duan Z, Buchholz TA, Hortobagyi GN, Goodwin JS, Giordano SH. Completion of adjuvant radiation therapy among women with breast cancer. Cancer. 2008 Jul 1;113(1):22-9. Erratum in: Cancer. 2008 Nov 1;113(9):2615
44. Du XL#*, Fang S, Meyer TE. Impact of Treatment and Socioeconomic Status on Racial Disparities in Survival among Older Women with Breast Cancer. American Journal of Clinical Oncology. 2008;31(2):125-132.
45. 方沈應,李遠貴,蘇景寬,徐德忠, 部隊人群甲肝疫苗接種的成本-效益分析. 解放軍預防醫(yī)學雜志, 2000,18(4):251-253.
46. 方沈應. 部隊人群乙肝疫苗接種決策分析. 解放軍預防醫(yī)學雜志, 1999,17(2):153-156.
47. 張治英,高紅麗,徐德忠,李遠貴,蘇景寬, 方沈應, 部隊甲型病毒性肝炎疫苗的接種策略. 第四軍醫(yī)大學學報, 2000年21卷10期